Vaxxinity (VAXX) 10-K 24 Mar 22 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 24, 2022	Jun. 30, 2021
Document Type	10-K
Entity Central Index Key	0001851657
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-41058
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line Two	Ste 3388
Entity Address, Address Line One	1717 Main St
Entity Address, City or Town	Dallas
Entity Address, Postal Zip Code	75201
Entity Address, State or Province	TX
Entity Tax Identification Number	86-2083865
Entity Registrant Name	VAXXINITY, INC.
Entity Ex Transition Period	false
Auditor Name	Armanino LLP
audit	32
Local Phone Number	244-5739
City Area Code	254
Title of 12(b) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	VAXX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
ICFR Auditor Attestation Flag	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Public Float			$ 0
Documents Incorporated by Reference	Portions of 2022 Annual Meeting of after December 31, 2021, pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended.
Entity Shell Company	false
Auditor Location	San Ramon, California
Document Annual Report	true
Class A Common Stock [Member]
Entity Common Stock, Shares Outstanding		111,966,892
Common Class B [Member]
Entity Common Stock, Shares Outstanding		13,874,132

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 144,885	$ 31,143
Accounts receivable	0	26
Amounts due from related parties	393	361
Prepaid expenses and other current assets	8,851	4,144
Total current assets	154,129	35,674
Deferred offering costs	0	2,254
Property and equipment, net	12,173	12,158
Restricted cash	172	55
Total assets	166,673	50,141
Current liabilities:
Accounts payable	3,192	1,017
Amounts due to related parties	19,407	8,004
Accrued expense and other current liabilities	4,519	2,744
Notes payable	376	619
Notes payable with related parties	0	2,294
Convertible notes payable	0	10,356
Convertible notes with related parties, net of discount	0	14,324
Total current liabilities	27,494	39,358
Other liabilities
Simple agreement for future equity	0	24,335
Notes payable, net of current portion	10,323	10,699
Warrant liability	0	400
Other long-term liabilities	237	249
Total liabilities	38,054	75,041
Preferred stock	0	0
Stockholders equity (deficit)
Class A treasury stock, par value of $0.0001; 0 and shares at December 31, 2021 and 2020, respectively	0	(23)
Additional paid-in capital	357,822	4,682
Accumulated deficit	(229,481)	(92,306)
Total stockholders equity (deficit)	128,619	(87,375)
Total liabilities, convertible preferred stock, and stockholders equity (deficit)	166,673	50,141
Convertible Preferred Stock [Member]
Other liabilities
Preferred stock	0	62,475
Series Seed Stock [Member]
Other liabilities
Preferred stock	0	10,383
Series Seed-1 Stock [Member]
Other liabilities
Preferred stock	0	20,903
Series Seed-2 Stock [Member]
Other liabilities
Preferred stock	0	11,315
Series A-1 Stock [Member]
Other liabilities
Preferred stock	0	4,640
Series A-2 Stock [Member]
Other liabilities
Preferred stock	0	15,234
Series A Preferred Stock [Member]
Other liabilities
Preferred stock	0	0
Series B Preferred Stock [Member]
Other liabilities
Preferred stock	0	0
Class A Common Stock [Member]
Stockholders equity (deficit)
Common stock:	278	272
Common Class B [Member]
Stockholders equity (deficit)
Common stock:	$ 0	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized/designated	50,000,000	57,298,376
Series Seed Stock [Member]
Preferred stock, shares authorized/designated	0	7,831,528
Preferred stock, shares issued	0	10,452
Preferred stock, share outstanding	0	10,452
Series Seed-1 Stock [Member]
Preferred stock, shares authorized/designated	0	23,021,458
Preferred stock, shares issued	0	22,876,457
Preferred stock, share outstanding	0	22,876,457
Preferred stock, liquidation preference	$ 0	$ 20,964,000
Series Seed-2 Stock [Member]
Preferred stock, shares authorized/designated	0	14,615,399
Preferred stock, shares issued	0	14,615,399
Preferred stock, share outstanding	0	14,615,399
Preferred stock, liquidation preference	$ 0	$ 11,360,000
Series A-1 Stock [Member]
Preferred stock, shares authorized/designated	0	5,522,300
Preferred stock, shares issued	0	1,871,511
Preferred stock, share outstanding	0	1,871,511
Preferred stock, liquidation preference	$ 0	$ 5,210,000
Series A-2 Stock [Member]
Preferred stock, shares authorized/designated	0	6,307,690
Preferred stock, shares issued	0	6,307,690
Preferred stock, share outstanding	0	6,307,690
Preferred stock, liquidation preference	$ 0	$ 14,660,000
Series A Preferred Stock [Member]
Preferred stock, shares authorized/designated	0	0
Preferred stock, shares issued	0	0
Preferred stock, share outstanding		0
Preferred stock, liquidation preference	$ 0	$ 0
Series B Preferred Stock [Member]
Preferred stock, shares authorized/designated	0	0
Preferred stock, shares issued	0	0
Preferred stock, share outstanding	0	0
Preferred stock, liquidation preference	$ 0	$ 0
Class A Common Stock [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	129,916,912
Common stock, shares issued	111,518,094	60,360,523
Common stock, shares outstanding	111,518,094	60,360,523
Treasury stock, shares	0	3,169,093
Common Class B [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	10,999,149
Common stock, shares issued	13,874,132	10,999,149
Common stock, shares outstanding	13,874,132	10,999,149

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Consolidated Statements of Income [Abstract]
Revenue	$ 66	$ 557
Cost of revenue	1,937	52
Gross (loss) profit	(1,871)	505
Operating expenses:
Research and development	71,379	20,570
General and administrative	51,825	12,217
Total operating expenses	123,204	32,787
Loss from operations	(125,075)	(32,282)
Other (income) expense:
Interest expense, net	840	1,182
Change in fair value of convertible notes	2,667	5,761
Change in fair value of simple agreements for future equity	8,365	615
Change in fair value of warrant liability	214	41
Loss on foreign currency translation, net	(23)	(77)
Other (income) expense	12,100	7,675
Loss before income taxes	(137,175)	(39,957)
Provision for income taxes	0	0
Net loss	$ (137,175)	$ (39,957)
Net loss per share, basic and diluted	$ (1.79)	$ (0.61)
Weighted average common shares outstanding, basic and diluted	76,586,842	65,638,946

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Series Seed Stock [Member]	Series Seed-1 Stock [Member]	Series Seed-2 Stock [Member]	Series A-1 Stock [Member]	Series A-2 Stock [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Class A Common Stock [Member]	Class B Common Stock [Member]	Common Stock [Member]	Common Stock [Member]Class A Common Stock [Member]	Common Stock [Member]Class B Common Stock [Member]	Preferred Stock [Member]	Preferred Stock [Member]Conversion To Class A Common Stock [Member]	Preferred Stock [Member]Series Seed Stock [Member]	Preferred Stock [Member]Series Seed-1 Stock [Member]	Preferred Stock [Member]Series Seed-2 Stock [Member]	Preferred Stock [Member]Series A-1 Stock [Member]	Preferred Stock [Member]Series A-2 Stock [Member]	Preferred Stock [Member]Series A Preferred Stock [Member]	Preferred Stock [Member]Series A Preferred Stock [Member]SAFEs [Member]	Preferred Stock [Member]Series A Preferred Stock [Member]Warrants [Member]	Preferred Stock [Member]Series A Preferred Stock [Member]Conversion To Class A Common Stock [Member]	Preferred Stock [Member]Series A Preferred Stock [Member]Convertible Debt [Member]	Preferred Stock [Member]Series A Preferred Stock [Member]Notes Payable, Related Parties [Member]	Preferred Stock [Member]Series B Preferred Stock [Member]	Preferred Stock [Member]Series B Preferred Stock [Member]Conversion To Class A Common Stock [Member]	Treasury Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2019	$ (48,512)										$ 270	$ 0		$ 26,819		$ 10,383	$ 16,436	$ 0	$ 0	$ 0									$ (23)	$ 3,590	$ (52,349)
Beginning balance, common shares at Dec. 31, 2019											37,953,692	0	0
Beginning balance, preferred shares at Dec. 31, 2019																7,831,528	8,017,771	0	0	0
Beginning balance, treasury shares at Dec. 31, 2019																													3,169,093
Issuance of common stock upon exercise of stock options, shares	283,290										283,290
Issuance of common stock upon exercise of stock options	$ 79										$ 1																			78
Issuance of stock, shares																	14,858,686	14,152,237	1,799,649
Issuance of stock											$ 33,001,408						$ 4,467	$ 10,955	$ 4,426
Conversion of stock, shares																		463,162		6,307,690
Conversion of stock																		$ 360		$ 15,234
Exercise of warrants, shares																			71,862
Exercise of warrants																			$ 214
Vesting of restricted stock, shares											121,282
Vesting of restricted stock	1										$ 1
Stock-based compensation expense	1,014																													1,014
Reclassification of common stock to Class A, shares											(60,360,523)	60,360,523
Reclassification of common stock to Class A											$ (272)	$ 272
Reclassification of common stock to Class B, shares											(10,999,149)		10,999,149
Net loss	(39,957)																														(39,957)
Ending balance at Dec. 31, 2020	$ (87,375)										$ 0	$ 272		62,475		$ 10,383	$ 20,903	$ 11,315	$ 4,640	$ 15,234	$ 0						$ 0		$ (23)	4,682	(92,306)
Ending balance, common shares at Dec. 31, 2020									60,360,523	10,999,149	(10,999,149)	60,360,523	10,999,149
Ending balance, preferred shares at Dec. 31, 2020		10,452	22,876,457	14,615,399	1,871,511	6,307,690	0	0								7,831,528	22,876,457	14,615,399	1,871,511	6,307,690	0						0
Ending balance, treasury shares at Dec. 31, 2020									3,169,093																				3,169,093
Issuance of common stock upon exercise of stock options, shares	186,204											485,836
Issuance of common stock upon exercise of stock options	$ 170																													170
Issuance of stock, shares	32,505,306								6,000,000			6,537,711															15,365,574
Issuance of stock	$ 103											$ 1															$ 122,791			103
Exhange of preferred stock, shares																(7,831,528)	(22,876,457)	(14,615,399)	(1,871,511)	(6,307,690)	53,502,585
Exchange of preferred stock																$ (10,383)	$ (20,903)	$ (11,315)	$ (4,640)	$ (15,234)	$ 62,475
Conversion of stock, shares																						4,539,060	134,106	(62,223,095)	3,624,114	423,230		(15,365,574)
Conversion of stock															$ (251,230)							$ 35,600	$ 614	$ (128,439)	$ 27,545	$ 2,205		$ (122,791)
Exercise of warrants, shares												112,373
Exercise of warrants	177																													177
Vesting of restricted stock, shares												15,405
Retirement of treasury stock in merger, shares												(3,169,093)																	3,169,093
Retirement of treasury stock in merger																													$ 23	(23)
Stock-based compensation expense	30,412																													30,412
Reclassification of common stock to Class A, shares												49,864,120
Reclassification of common stock to Class A	251,230											$ 5																		251,225
Reclassification of common stock to Class B, shares												(2,874,983)	2,874,983
Net loss	(137,175)																														(137,175)
Ending balance at Dec. 31, 2021	$ 128,619											$ 278		$ 0		$ 0	$ 0	$ 0	$ 0	$ 0	$ 0						$ 0		$ 0	$ 357,822	$ (229,481)
Ending balance, common shares at Dec. 31, 2021									111,518,094	13,874,132		111,518,094	13,874,132
Ending balance, preferred shares at Dec. 31, 2021		0	0	0	0	0		0								0	0	0	0	0	0						0
Ending balance, treasury shares at Dec. 31, 2021									0																				0

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Series Seed-1 Stock [Member]
Issuance of stock, issuance costs		$ 18
Series Seed-2 Stock [Member]
Issuance of stock, issuance costs		45
Series A-1 Stock [Member]
Issuance of stock, issuance costs		585
Series A-2 Stock [Member]
Issuance of stock, issuance costs		41
Series B Preferred Stock [Member]
Issuance of stock, issuance costs		$ 133
Common Stock [Member] | Class A Common Stock [Member]
Issuance of stock, issuance costs	$ 13,913

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (137,175)	$ (39,957)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	1,102	717
Amortization of debt issuance costs	261	108
Change in fair value of Series A preferred stock	30,412	1,014
Stock-based compensation expense	280	0
Non-cash interest expense	0	582
Change in fair value of convertible notes	2,667	5,761
Change in fair value of warrant liability	214	41
Change in fair value of simple agreements for future equity	8,365	615
Changes in operating assets and liabilities:
Accounts receivable	26	(26)
Amounts due to related parties	(31)	(1,743)
Prepaid expenses and other current assets	(4,704)	(3,488)
Deferred offering costs	2,254	(2,254)
Accounts payable	2,174	(267)
Amounts due to related parties	11,402	4,608
Accrued expenses and other current liabilities	1,775	285
Other liabilities	(12)	94
Net cash used in operating activities	(80,990)	(33,910)
Cash flows from investing activities:
Purchase of property and equipment	(1,318)	(1,477)
Net cash used in investing activities	(1,318)	(1,477)
Cash flows from financing activities:
Proceeds from issuance of convertible notes payable with related parties	2,000	12,040
Repayment of convertible notes	(2,000)	(5,500)
Repayments Of Related Party Debt	414	202
Repayments Of Medium Term Notes	100	0
Payment of debt issuance costs for related party convertible notes	(300)	0
Proceeds from Paycheck Protection Program	257	0
Proceeds from exercise of stock options	79	170
Net cash provided by financing activities	66,109	196,167
Increase in cash, cash equivalents, and restricted cash	30,722	113,859
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance	31,198	476
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance	145,057	31,198
Supplemental Disclosure
Cash paid for interest	581	425
Noncash Financing Activities
Acquisition of airplane through issuance of note payable	0	11,500
Fair value of warrants issued in connection with preferred stock issuance	0	573
Reitrement Of Treasury Shares	0	23
Fair Value of Restricted Stock, Vested	0	1
Series Seed-1 Stock [Member]
Proceeds from issuance of convertible preferred stock, net of issuance costs	4,467	0
Series Seed-2 Stock [Member]
Proceeds from issuance of convertible preferred stock, net of issuance costs	10,955	0
Series B Preferred Stock [Member]
Proceeds from issuance of convertible preferred stock, net of issuance costs	0	122,791
Series A-1 Stock [Member]
Proceeds from issuance of convertible preferred stock, net of issuance costs	4,999	0
Series A-2 Stock [Member]
Payment for convertible preferred stock issuance costs	(41)	0
Class A Common Stock [Member]
Proceeds from issuance of convertible preferred stock, net of issuance costs	0	71,077
Simple Agreement for Future Equity [Member]
Proceeds from issuance of convertible preferred stock, net of issuance costs	39,355	2,900
Conversion Of Stock Amount Issued 1	35,600	0
Series A and Series B to Class A Common Stock [Member]
Conversion Of Stock Amount Issued 1	251,230	0
Series Seed, Series Seed-1, Series Seed-2, Series A-1 and Series A-2 for Series A [Member]
Conversion Of Stock Amount Issued 1	62,475	0
Convertible Notes Payable to Series A Preferred [Member]
Conversion Of Stock Amount Issued 1	27,545	0
Notes Payble to Series A Preferred [Member]
Conversion Of Stock Amount Issued 1	2,205	0
Warrant to Series A Preferred [Member]
Conversion Of Stock Amount Issued 1	614	0
Warrant to Class A Common Stock [Member]
Conversion Of Stock Amount Issued 1	177	0
SAFE to Series A2 Preferred [Member]
Conversion Of Stock Amount Issued 1	0	15,275
SAFE to Seed2 Preferred [Member]
Conversion Of Stock Amount Issued 1	0	360
Warrant to Series A1 Preferred [Member]
Conversion Of Stock Amount Issued 1	$ 0	$ 214

Nature of the Business

Nature of the Business	12 Months Ended
	Dec. 31, 2021
Nature of the Business [Abstract]
Nature of the Business	1. Nature of the Business Vaxxinity, combination of two from UBI and a second spin-out from UBI in (“COVAXX”). and on March 2, 2021, did so by acquiring all of the outstanding equity interests of UNS and COVAXX exchange contributed their equity interests in each of UNS and COVAXX in exchange for equity in Vaxxinity The Company is a and coronaviruses utilizing the therapeutic vaccines to combat chronic disorders a significant shareholder of the Company and, therefore, considered a related party. The Company is limited competitors of of proprietary technology, successfully commercialize any The including extensive pre-clinical amounts of additional capital, assurance that intellectual property approved products will if ever, the Company will generate significant revenue technology and is dependent upon the services of its employees and consultants. Contribution and Exchange Agreement On March preferred stock options to purchase common stock in Vaxxinity, for a warrant to acquire common stock in contributed to Vaxxinity and the holders of such notes received Series A preferred stock in Vaxxinity. • Each UNS common share and convertible preferred share was exchanged for 0.2191 shares of Vaxxinity common stock or Series A preferred stock, as applicable; • Each share of COVAXX 3.4233 stock or Series A preferred stock, as applicable (and prior to the closing of the Reorganization, all the holders of outstanding COVAXX then exchanged for shares of Vaxxinity’s • The Reorganization Convertible Notes were exchanged for an aggregate of 4,047,344 preferred stock; and • Each outstanding option of both UNS and COVAXX to purchase common shares of UNS or COVAXX substituted with an option to purchase shares of Class A common stock of Vaxxinity. exchanged based on a conversion ratio of 0.2191 . Each outstanding COVAXX ratio of 3.4233 . All parties exchange for purposes that is governed by Section 351(a) of the Internal Revenue Code of 1986, as amended. The Reorganization was liabilities Reorganization are presented on a consolidated basis. Reverse Stock Split On October 29, 2021, 1.556 Class B common stock the Company’s amounts including the notes have been retroactively adjusted have resulted from the Stock Split have been rounded down to the nearest whole share. Initial Public Offering On November 15, 2021, the Company closed its IPO of 6,000,000 13.00 per share. On November 18, 2021 537,711 common stock 900,000 stock at after deducting 71.1 million. Upon the closing of the IPO, all previously outstanding shares of the automatically converted at the same ratio used for the Stock Split (1-for- 1.556 ) into shares of its Class A common stock. Liquidity As of December 31, 2021, the Company its operations Convertible Notes), a portion cash flows from operations since used in has an accumulated deficit of $229.5 million. The Company expects to incur substantial operating losses and negative cash flows from operations for existing cash and next 12 months. The Company will need to obtain additional funding beyond the period that is 12 months from the date these financial statements were available to be issued such sufficient capital development Company would otherwise prefer to develop and market itself. The accompanying consolidated financial statements have been prepared on a of adjustments relating to the might result from the outcome of the uncertainties described above. Impact of COVID-19 Pandemic In March 2020, the World Health Organization declared the outbreak of a and to date, has public health safety measures. The Company is closely monitoring the impact of its operations and extent of potential delays or impacts on its business, its clinical trials, its research programs, healthcare systems or and it cannot presently predict the scope and severity of any potential business shutdowns or disruptions. The extent to which COVID-19 uncertain and cannot be predicted with confidence, such as the severity of COVID-19 or of the third parties with whom the Company engages, however, to conduct its business have a material adverse impact on its business, results of operation and financial condition. The Company has not incurred impairment losses aware of any specific related event or circumstance that would require it to revise its estimates reflected in these consolidated financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of presentation The accompanying consolidated financial statements have States of America (GAAP) for financial reporting. The consolidated were parties to the Contribution and Exchange Agreement. All share and per share amounts, as been converted Agreement and the Stock Split ratio. Foreign currency translation The functional currency rates and monetary assets and liabilities are accounts are (losses) gains in the consolidated statements of operations. Segment information Operating segments are reviewed by assessing performance. The Company’s as a single operating segment and has one reportable segment. Use of estimates The preparation of consolidated and assumptions that affect the reported amounts of assets and liabilities and the consolidated financial statements and the reported amounts of expenses during within these consolidated financial statements include, but are not limited to, the estimated fair value of the Company’s common and convertible notes payable, simple agreements for future equity, warrant liabilities, stock-based compensation, income tax valuation allowance and the trends and other market-specific management evaluates estimates or assumptions. Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be equivalents with financial institutions, in of the Company’s cash management policy cash flow requirements, and to attain a market rate of return. Restricted cash Concentration of credit risk Financial instruments Cash equivalents are and accredited financial associated with form of a money market account with a financial institution that management believes to be creditworthy. The Company is dependent on contract manufacturers, several of whom are considered to be related parties, for manufacturing, quality control, immunosorbent assay (“ELISA”) tests, and for research as research and manufacturers. Accounts receivable The receivable for estimated written off Company has not recorded any allowance for bad debts against the trade accounts receivable. Property and equipment Property and equipment are estimated useful life of the assets. The estimated useful life of property and equipment is as follows: Upon retirement or sale, the cost of assets resulting gain or incurred. Impairment of long-lived assets Long-lived circumstances indicate deciding significant negative industry or review expected to recognized when estimated undiscounted future cash flows expected to result from the use of an asset The impairment loss would be discounted cash flows. To date, the Company has not recorded any impairment losses or disposals on long-lived assets. Deferred offering costs The Company capitalizes certain financing effort recorded deferred offering costs are expensed immediately as a charge to operating expenses in the statement of operations. Fair value measurements Certain assets and liabilities an asset or paid to transfer a liability (an transaction between market participants on the measurement date. Valuation use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets that are identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices corroborated by observable market data. Level 3—Unobservable inputs that are supported by assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Prior to the conversion in accordance and all of the simple agreement 3 liabilities. Convertible notes payable The Company issued payable at fair value in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”). The notes payable with related parties are from the over the term of the convertible notes using the effective interest method in the accompanying consolidated statements of operations. On March 2, 2021, each convertible note that was outstanding was exchanged for shares of Series A preferred stock (see Debt issuance costs The Company records term of the debt using operations. Simple Agreement for Future Equity—SAFE The Company accounts for SAFEs at reporting period, with changes in fair value recognized in the accompanying consolidated statements of operations. On March 2, 2021, Classification of convertible preferred stock The Company by its terms. The Company’s convertible preferred stock is classified have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company. All shares concurrently with the closing of the initial public offering (see Note 10). Revenue recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts With Customers (“ASC 606”). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or consideration that with customers only when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Company assesses the evaluating management to make judgments about the individual promised goods or services, the intended benefit of good or distinct, an entity is required to combine that good or service with other promised goods or services or services that is distinct. If the consideration promised in a contract includes a variable amount, the Company will be variable consideration by using the most likely amount method and applies the constraint on variable consideration, which requires the amount included in the revenue recognized consideration included in the transaction price price. The Company recognizes as revenue the (or as) each performance obligation is satisfied, either at a of an output or input method. In the Company’s sole revenue contract, the performance obligation was satisfied at the point in time the data and related samples were made available for the customer’s review. For its sales of ELISA tests, the Company recognizes revenue once control is transferred upon delivery to the customer. Taiwan Centers for Disease Control grant United managing COVID-19 vaccine development. trial in Taiwan. achievement activities involved in completing the clinical trials in relation to the milestones. The Company accounts for the amounts that have been received from the CDC as contra research and development expenses in the accompanying consolidated statements of operations. Research and development Research compensation and other corporate costs attributable to research and development activities and are expensed as incurred. The Company has entered into various research, development and manufacturing contracts, some of which are with related parties (see Note 18). These expenses as incurred. liabilities, the Company contracted costs. The Company’s historical accrual estimates have not been materially different from the actual costs. Patent costs Patent-related costs relating to the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. Stock-based compensation The Company measures all stock-based awards granted to employees, directors and non-employees based on the fair of grant and recognizes compensation of the respective award. Forfeitures are accounted for as they occur. The Company classifies the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. Prior to value of its common stock was determined by its most recently available third-party valuations of common stock. There are significant judgments assumptions include sold shares of preferred the likelihood used in the valuations could result in different fair values of common stock at each valuation date. The fair value of each restricted stock award is estimated on on that same (“Black-Scholes”), which expected term 2021, lacks sufficient company-specific stock volatility based on time as it has adequate has been determined utilizing the “simplified” method for awards that qualify as granted to non-employees is equal to the the U.S. Treasury yield curve in effect at award. Expected dividend expect to pay any cash dividends in the foreseeable future. Performance-based options The Company accounts for performance-based options according to the ASC 718, Compensation – Stock Compensation ("ASC 718"), which are subject to different accounting depending on whether they meet the definition of performance conditions, market conditions, or other conditions. The condition satisfying the performance and market conditions. of the performance condition was determined deferred until assigned to the market condition will be recognized as expense according to the derived service period in the Income taxes The Company accounts for which requires the recognized difference between the the differences are expected to reverse. Company assesses available evidence, that is established through a charge to income tax all available positive and negative evidence, including recent financial operations. The process to determine that it sustained, the tax position is then amount of the settlement. To include the related net interest and penalties. Net loss per share The Company of participating according to dividends declared or accumulated, and participation rights available to rights to receive dividends as if all income for the period had been distributed. Basic net period. Diluted net loss is computed by securities. Diluted net outstanding for restricted stock and convertible preferred stock are considered potential dilutive common stock and are excluded from the computation of net loss per share as their effect is anti-dilutive. The Company’s contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a diluted net loss per share is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to be outstanding if their effect is anti-dilutive. Emerging growth company status The Company is an “emerging growth company” (“EGC”), as defined in the Jumpstart Our Business Startups Act (“JOBS Act”) and is permitted to and plans to companies that are not EGCs. The Company the JOBS implementation of new or revised accounting standards. The Company has therefore, as long as the Company remains they become applicable to other public companies that are not EGCs. December 31, 2021 2020 Cash and cash equivalents $ 144,885 $ 31,143 Restricted cash 172 55 Total cash, cash equivalents and restricted cash $ 145,057 $ 31,198 Estimated Useful Life Airplane 15 years Facilities 15 years Furniture and fixtures 5 years Vehicles 5 years Laboratory and computer equipment 3 years Software 3 years

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Fair Value Measurements [Abstract]
Fair Value Measurements	3. Fair Value Measurements The Company's money assets. The value for the Convertible Notes, SAFE and observable in the market, which represents a Level 3 measurement within the fair value hierarchy. In accordance with the Contribution and Exchange stock. The following indicate the level of the fair value hierarchy used to determine such fair values (in thousands): During the years ended December 31, 2021 and 2020, there were no Convertible Notes During the years ended December 31, 2021 and of the Convertible Notes were required to the Convertible Notes requiring a fair value hierarchy wherein fair value is estimated using significant unobservable inputs. Convertible Notes requiring a measurement to fair value are as follows (in thousands): The probability assumptions on multiple conversion scenarios, discount rates and interest rates. In accordance with the Contribution and Exchange Agreement, on March 2, 2021, the Convertible Notes were preferred stock. Simple Agreement for Future Equity—SAFE During the years ended December 31, 2021 and 2020, the Company executed SAFE arrangements. The fair value of the SAFEs on the date of issuance into preferred stock 35.6 December 31, 2021 and $ 15.6 The following table sets forth a summary of the activities of the SAFE arrangements, which represents a recurring measurement that is classified within Level 3 In accordance with stock. Warrants to Purchase Series A-1 Convertible Preferred Stock & Common Stock In connection with the fully vested 205,970 assistance with the recorded as a reduction in the proceeds received from the sale. The warrants were issued to advisors of the company and represented non-variable contingently redeemable instruments. warrants were accounted for as liabilities and adjusted to fair value at each reporting period. The warrants are exercisable on the date of issuance and have an exercise price of $ 0.003 In December 2020, warrants were exercised for 71,862 0.003 $ 1,000 . 134,106 continued to re-measure the fair value of connection with the IPO, converted into Class A common stock. The classified within Level 3 December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market account $ — $ — $ — $ — Total assets $ — $ — $ — $ — Liabilities: Convertible notes payable $ — $ — $ 10,356 $ 10,356 Convertible notes with related parties — — 14,324 14,324 SAFEs — — 24,335 24,335 Warrant liability — — 400 400 Total liabilities $ — $ — $ 49,415 $ 49,415 December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market account $ 139,794 $ — $ — $ 139,794 Total assets $ 139,794 $ — $ — $ 139,794 Convertible Notes Balance at December 31, 2019 $ 12,121 Issuance of convertible notes 12,040 Repayments (5,500) Change in fair value 5,761 Issuance costs (300) Amortization of issuance costs 83 Accrued interest 475 Balance at December 31, 2020 24,680 Issuance of convertible notes 2,000 Repayments (2,000) Change in fair value 2,667 Amortization of issuance costs 217 Accrued interest 168 Interest paid (187) Conversion to Series A preferred stock (27,545) SAFE Liability Balance at December 31, 2019 $ — Issuance of SAFEs 39,355 Change in fair value 615 Conversion to Series Seed-2 convertible preferred stock (360) Conversion to Series A-2 convertible preferred stock (15,275) Balance at December 31, 2020 24,335 Change in fair value 8,365 Issuance of SAFEs 2,900 Conversion to Series A preferred stock (35,600) Warrant Liability Balance at December 31, 2019 $ — Issuance of Series A-1 preferred warrants 573 Exercise of warrants (214) Change in fair value 41 Balance at December 31, 2020 400 Change in fair value 214 Conversion to warrants for shares of Series A preferred stock (614)

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2021
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): December 31, 2021 2020 Deposits $ 4,379 $ 10 Prepaid materials and supplies 4,131 3,302 Other 341 832 $ 8,851 $ 4,144 The Company’s 1.0 $ 2.5

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2021
Property and Equipment [Abstract]
Property and Equipment	5. Property and Equipment Property and equipment, net consisted of the following (in thousands): December 31, 2021 2020 Airplane $ 11,983 $ 11,983 Laboratory and computer equipment 1,831 969 Software 168 — Vehicles 87 — Facilities, furniture and fixtures 85 84 Total property and equipment 14,154 13,036 Less: accumulated depreciation (1,981) (878) Property and equipment, net $ 12,173 $ 12,158

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2021
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	6. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): December 31, 2021 2020 Accrued bonuses $ 2,294 $ 2,187 Accrued external research and development 1,501 296 Accrued professional fees and other 692 228 Accrued interest 32 33 $ 4,519 $ 2,744

Other Long-Term Liabilities

Other Long-Term Liabilities	12 Months Ended
	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Other Long-Term Liabilities	7. Other Long-Term Liabilities Other long-term liabilities consisted of the following (in thousands): December 31, 2021 2020 Accrued tax provision 236 236 Accrued rent 1 13 $ 237 $ 249 As of 0.2 may be subject to paying for late filing fees related to a foreign subsidiary. The Company expects these amounts to be forgiven but has accrued for them until the statute of limitations expires and it is appropriate to write them off.

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2021
Notes Payable [Abstract]
Convertible Notes Payable	8. Convertible Notes Payable Beginning in April 2018, the Notes bear simple interest at annual rates 4.8 % to 6 %. All unpaid principal, together with payable upon an event provisions addressing automatic and optional conversion, events of default, and prepayment provisions. The Company recognized through the consolidated statements of operations. In outstanding was exchanged Contribution and Exchange Agreement. During 0.2 0.7 respectively, related to the Convertible Notes. In addition, in the years ended December 31, 2021 and 2020, the Company recognized a change 2.7 5.7 Convertible Notes, respectively. The following table shows the activity of the Convertible Notes (in thousands): Convertible Notes Principal Amount Payable Change in Fair Value Accrued Interest Issuance Conversion to Standard Related Party Standard Related Party Standard Related Party Costs Series A Balance December 31, 2019 $ 11,170 $ 510 $ 33 $ 26 $ 378 $ 4 $ — $ — $ 12,121 Additions 2,040 10,000 1,884 3,822 560 179 (300) — 18,185 Settlements (5,500) — 55 — (264) — — — (5,709) Amortization — — — — — — 83 — 83 December 31, 2020 7,710 10,510 1,972 3,848 674 183 (217) — 24,680 Additions — 2,000 812 1,855 58 110 — — 4,835 Settlements (2,000) — — — (187) — — — (2,187) Amortization — — — — — — 217 — 217 Conversion of Convertible Notes to Series A preferred stock (5,710) (12,510) (2,784) (5,703) (545) (293) — (27,545) (27,545) December 31, 2021 $ — $ — $ — $ — $ — $ — $ — $ (27,545) $ —

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2021
Notes payable with related parties [Abstract]
Notes payable with related parties [Text Block]	9. Notes Payable Notes Payable with Related Parties In December 2018, the Company entered into Convertible Notes, the 2.0 Related 5 % prepayment. In accordance with the Contribution and Exchange Agreement, on March 2, 2021, into Series A preferred stock. During the years ended December 0.1 Related Notes. 2019 Executive Note In November 2019, the Company borrowed 0.1 agreement was executed. However, 5 %, consistent with conditions of the Convertible Notes and 2018 Related Notes, which was the closest benchmark the Company could evaluate. The 2019 Executive Note was repaid in August 2021. The activity of the 2018 Related Notes and 2019 Executive Note is as follows (in thousands): Note Payable—Airplane In connection with the acquisition for $ 11.5 3.4 % and a maturity date of June 9, 2025. Principal and interest payments are payable monthly in the 0.07 9.4 of the Company. In addition, the Company incurred debt issuance costs of $ 0.3 loan. There are no financial covenants associated with the 2025 Note. The carrying value of the 2025 Note is as follows (in thousands): As of December 31, 2021, the remaining principal payments for the 2025 Note, are as follows (in thousands): Interest expense 0.4 0.2 respectively. As of December 31, 2021, accrued interest of less than $ 0.1 in the accompanying consolidated balance sheets. Note Payable—Paycheck Protection Program The Company Association (“HSBC”) in the 0.3 Program (“PPP”). The for loans to qualifying businesses for December 31, 2021, there were no events of default under the PPP Loan. The Company paid off the PPP Loan in full, including all accrued but unpaid interest to the repayment date, in August 2021. 2018 Related Notes and 2019 Executive Note Related Party Principal Accrued Interest Balance December 31, 2019 $ 2,100 $ 88 $ 2,188 Additions — 106 106 December 31, 2020 2,100 194 2,294 Accrued interest — 19 19 Repayment (100) — (100) Interest paid — (8) (8) Conversion (2,000) (205) (2,205) December 31, 2021 $ — $ — $ —

Convertible Preferred Stock

Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2021
Convertible preferred stock [Abstract]
Convertible preferred stock	10. Convertible Preferred Stock In connection with the Reorganization, each 0.2191 stock and each 3.4233 the first 122.8 stock financing. The Company issued 15,365,574 8.00 preferred stock As of December 31, 50,000,000 stock with a par value of $ 0.0001 The table below stock concurrently with the of the stock split described in Note 1.

Simple Agreement for Future Equ

Simple Agreement for Future Equity	12 Months Ended
	Dec. 31, 2021
Simple Agreement for Future Equity [Abstract]
Simple Agreement for Future Equity	11. During the years redeemable, contained a liquidity require the Company to settle the SAFE obligation by transferring assets or cash. For this reason, the Company recorded the SAFEs as a liability earnings. In 0.4 463,162 convertible preferred stock at $ 0.7773 (“SAFE 2”) for $ 14.7 6,307,690 at $ 2.3241 The Company determined the fair value value on the date of conversion and the initial fair value of SAFE 2 investment in the consolidated statements of operations. In December 2020, the Company 24.3 issued additional SAFEs for $ 2.9 Equity Financing —Upon initial closing of a 50.0 greater of (1) the number of price per share equal promised options, and divided by the discount eighty percent (80%). Liquidity Event —If there is a liquidity receive a concurrent with, the consummation of such the number of shares of common stock equal to the purchase amount divided by the liquidity price, as outlined in the agreements. Dissolution Event —If there is a dissolution event, as described in the agreements, before the automatically be purchase amount, due and payable to the investor immediately prior to the consummation of the dissolution event. Termination —SAFE 3 will automatically terminate immediately following the the investor pursuant due the investor. into shares of Series A-3 preferred stock of COVAXX, The Agreement. Prior to the Reorganization, Series A-3 preferred stock of COVAXX,

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2021
Common Stock [Abstract]
Common Stock	12. Common Stock As explained common 60,360,523 Vaxxinity’s 10,999,149 was exchanged for 0.2191 3.4233 shares of Vaxxinity In June 2021, the Company converted 2,874,983 Executive Chairman on a one-to-one basis for shares of Class B common stock. As of December 31, 2021, 1,100,000,000 stock 0.0001 1,000,000,000 100,000,000 Holders of Class as otherwise expressly provided law, holders of our Class B common stock will be entitled to ten votes per share on all matters submitted to a vote of stockholders. Holders of stockholders, except (i) amendments to Vaxxinity’s Certificate of Incorporation to increase or decrease the par value of a class of capital stock, in which case the applicable class would be required to vote separately to approve the proposed amendment and (ii) amendments to Vaxxinity’s of Incorporation holders adversely, in which case the applicable class would be required to vote separately to approve the proposed amendment. Holders of common stock are legally available therefor if the board of directors, in its discretion, determines to issue dividends. The voting, preferences of the holders of Vaxxinity’s The Company has reserved shares of common stock for issuance for the following purposes: December 31, 2021 2020 Series Seed preferred — 7,831,528 Series Seed-1 preferred — 22,876,457 Series Seed-2 preferred — 14,615,399 Series A-1 preferred — 1,871,511 Series A-2 preferred — 6,307,690 Options issued and outstanding 21,387,909 9,276,399 Options available for future grants 7,209,538 1,897,049 Warrants issued and outstanding 1,928,020 86,186 30,525,467 64,762,219

Equity Incentive Plan

Equity Incentive Plan	12 Months Ended
	Dec. 31, 2021
Equity Incentive Plan [Abstract]
Equity Incentive Plan	December 31, 2021 2020 Risk-free interest rate 0.59% - 1.35% 0.34% - 0.38% Expected term (in years) 5.00 - 6.30 5.60 - 6.08 Expected volatility 71.60% - 93.40% 70.90% - 86.84% Expected dividend yield 0.00% 0.00% Number of Stock Options Outstanding Weighted Price Per Share Weighted Contractual Term (years) Aggregate Intrinsic Value (in thousands) Balance at December 31, 2019 7,610,289 $ 0.33 8.6 $ 2,357 Granted 2,672,152 1.17 Exercised (283,290) 0.29 Forfeited (722,752) 0.29 Balance at December 31, 2020 9,276,399 $ 0.60 7.6 $ 8,415 Granted 13,482,915 8.20 Exercised (186,204) 0.91 Forfeited (1,185,201) 2.98 Balance at December 31, 2021 21,387,909 $ 5.25 7.4 $ 49,684 Options vested and exercisable at December 31, 2021 13,439,566 $ 4.40 6.8 $ 37,969 Number of Shares Weighted Average Grant Date Fair Value Per Share Unvested at December 31, 2020 15,405 $ 0.50 Vested (15,405) (0.50) Unvested at December 31, 2021 — $ — Years 2021 2020 Research and development $ 1,343 $ 243 General and administrative 29,069 771 Total stock-based compensation expense $ 30,412 $ 1,014 13. Equity Incentive Plan Stock Options In March 2021, the Grant restricted Company’s 21,593,830 stock pursuant to awards. In 6,362,455 exchange for an equal number of options to purchase shares of Class B common stock. The Company accounted for this exchange as a stock option modification. In November 2021, Plan”), which rights, (including fully 2021 Plan. The following is a summary of certain terms and conditions of the New 2021 Plan. The maximum number of 8,700,000 As 7,209,538 Company prior to vesting, satisfied without the issuance terminated, other than by exercise, shall be added back to the Shares available for issuance under the New 2021 Plan. The exercise directors. Any incentive options granted to persons possessing less than 10% of the total combined voting power of all classes of stock may not have an exercise price granted to persons possessing more than 10% of the total combined voting power of all classes of stock may not have an exercise price of less than 110% of the fair market value of the common stock on the grant date. The option term for incentive awards may not be greater than ten years from the date of the grant. Incentive options granted to persons possessing more than 10% of years from the date of the grant. The vesting period for equity-based awards is determined at the discretion of the board of directors. As of December 15,025,454 6,362,455 Class B stock outstanding, 8,652,630 4,786,936 31, 2021, the maximum number of stock options awards available for future issuance under the Company’s plans is 7,209,538 . Stock Option Activity The following table summarizes stock option activity for the years ended December 31, 2021 and 2020: The aggregate intrinsic value of options common stock for those options that had exercise prices lower than the fair value of the common stock. The intrinsic value of options exercised during each of the years ended December 31, 2021 and 2020 were less than $ 0.1 The weighted-average grant-date fair 4.21 and $ 0.50 , respectively. The 24.5 0.8 respectively. Valuation The fair option valuation model 2021 and 2020: In August 2021, the Hu in exchange as a stock option modification. value-based measures original award immediately before the modification. Stock Options Granted to Employees that Contain Performance and Market Conditions Included in 6,799,625 Class A Peter Diamandis. In August 2021, the stock option awards for the Mei Mei Hu and Louis Reese totaling 5,983,670 an equal number of options to purchase shares modification. The fair value of the 23.8 using the Monte-Carlo simulation model. The assumptions used in the Monte-Carlo simulation model were as follows: The stock option awards for Peter Diamandis totaling 815,955 0.3 in the Monte-Carlo simulation model were as follows: The compensation over the derived service period for the market-based criteria. The condition for the market-based criteria in the stock options was based on the future price of the Company's common stock trading at or above a 5,439,700 6,799,625 shares containing performance- condition achieved through the Company’s not been achieved. Restricted Stock The following table summarizes the Company’s restricted stock activity for the year ended December 31, 2021: The aggregate fair value of restricted stock that vested was less than $ 0.1 Stock-based compensation expense 2020. Stock-Based Compensation Expense The statements of operations (in thousands): As of December 31, 2021, total 26.8 is expected to be recognized over a weighted average period of 3.3

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Taxes [Abstract]
Income Taxes	14. Income Taxes The sources of outside of the U.S., are as follows (in thousands): Years Losses before taxes 2021 2020 Domestic entities $ (128,538) $ (31,053) Entities outside the U.S. (8,636) (8,904) (137,175) $ (39,957) Years 2021 2020 Current: Federal $ — $ — State and local — — Foreign — — Total current tax expense — — Deferred tax (benefit): Federal — — State and local — — Foreign — — Total deferred tax (benefit) — — Years 2021 2020 Income taxes at statutory rate 21.00 % 21.00 % State income taxes, net of federal benefit 0.50 % 0.29 % Stock compensation (3.65) % % Foreign rate differential (0.74) % (4.06) % Uncertain tax positions 0.00 % 0.00 % Other (1.90) % (0.36) % Change in valuation allowance (15.21) % (16.87) % Provision for income taxes 0.00 % 0.00 % As of December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 32,405 $ 12,373 Compensation accruals 1,735 377 Other 27 627 Total deferred tax assets 34,167 13,377 Less: valuation allowance (34,106) (13,247) Net deferred tax assets $ 61 $ 130 Deferred tax liabilities: Depreciation $ (61) $ (130) Net deferred tax liabilities (61) (130) Net deferred income taxes $ — $ — Years 2021 2020 Uncertain tax position liability at the beginning of the year $ 652 $ 646 Increases (decreases) related to tax positions taken during current period — 6 Uncertain tax position liability at the end of the year $ 652 $ 652 Tax Expense (Benefit) The components of the provision for income taxes are as follows for the years ended December 31, 2021 and 2020 (in thousands): Tax Rate Reconciliation The Company’s effective tax rate for the years ended December 31, 2021 and 2020 was 0.00 % and 0.00 %, respectively. A reconciliation is as follows (in thousands): Deferred Tax Assets (Liabilities) The Company computes income taxes using measured by enacted rates, attributable liabilities. In deferred tax income valuation allowance against its net deferred tax assets for December 31, 2021 more likely than not that these assets will not be fully realized based on a current evaluation of expected future Company is in a cumulative loss 6.7 and $ 20.9 The Company reevaluates the positive and negative evidence at each reporting period. Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands): Net Operating Losses The Company had total net 134.6 44.5 of December 31, 2021 and 2020, respectively, that have no expiration date. The Company has foreign net operating loss carryforwards of $ 24.0 20.2 Utilization limitations provided by Company has not changes since additional ownership changes of the under the Code. The annual limitation may result in the expiration of the credit carryforwards would be removed from On March 27, 2020, the President of the United States signed into law the CARES Act, which, along with earlier issued IRS guidance, contains numerous provisions that may benefit the Company, Company. The CARES Act did not have a material impact on the Company’s tax provision for the year ended December 31, 2021. The Consolidated Appropriations Act, 2021, which was enacted on December 27, 2020, has expanded, extended, and clarified selected CARES Act provisions, specifically on Paycheck Protection Program loan business meals as well as tax provision for the year ended December 31, 2021. The Company subject to income tax examinations by U.S. federal, state and local for tax years 2017 and future periods. The company is not currently under audit for any US federal or state or foreign income tax audits. Uncertain Tax Positions A summary of the Company’s unrecognized tax benefits activity and related information is presented as follows (in thousands): The unrecognized tax benefits 0.6 tax remaining unrecognized tax benefits 0.1 recognizes accrued interest 0.2 and penalties related to prior year’s tax filings, as of December 31, 2021. The Company limitations for examination 2017 and future periods.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2021
Net Loss Per Share [Abstract]
Net Loss Per Share	15. Net Loss Per Share The Company’s unvested restricted common shares have been excluded from the computation of basic net loss per share. The convertible preferred stock, have been excluded from the computation of diluted net loss per share as the effect net loss per share. Therefore, the weighted loss per share is the same. The Company each period end, from the have had an anti-dilutive effect: December 31, 2021 2020 Series Seed preferred — 7,831,528 Series Seed-1 preferred — 22,876,457 Series Seed-2 preferred — 14,615,399 Series A-1 preferred — 1,871,511 Series A-2 preferred — 6,307,690 Unvested restricted stock — 23,970 Options and RSUs issued and outstanding 21,387,909 14,434,095 Warrants issued and outstanding stock 1,928,020 134,106 23,315,929 68,094,756

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Contractual Obligations The Company and contract manufacturing organizations (“CMOs”) to produce vaccines and other potential product candidates. Contracts with CROs and CMOs are generally cancellable, with notice, at the Company’s option. As of December 31, 2021, the Company had remaining prepayments to CROs of $ 1.6 $ 2.5 product candidate. Michael J. Fox Foundation Grant On November 3, 2021, the the amount of $ 0.8 UB-312, an a -Synuclein immunotherapy. and expected to to short-term offset. The Company recognizes payments from MJFF as a reduction of research expenses that cash/deposits, cash/deposits and the 0 corresponding 0 . 0.1 million as a reduction of research and development expenses for amounts reimbursed through the grant. Lease Agreements The Company has multiple operating lease agreements for office and laboratory space that extend through August 2022. The Company records total expense on a straight-line basis over the term of the lease agreement. One of the Company’s to provide a security deposit in the amount of less than $ 0.1 its leases. Rent expense 0.1 0.1 In August 2021, 5,012 commencing August 0.2 License Agreements In October 2014, the Company assets and intellectual property. 32,505,306 exploitation of all amended in pursue indications outside the initial field limitations. In connection with the amendment, developed by the Company outside the original upon. The Company terms for the license at prevailing UBI upfront fees, revenue royalties, development milestones, commercial milestones, sublicense fees, and other related Vaxxinity’s US Holdings, LLC, all exclusive rights against all coronaviruses perpetual, exclusive and fully paid-up. Company has the right to grant sublicenses. The account for the issuance of common party did not have any basis in the assets licensed, so there was no accounting impact for the Company. In August 2021, Vaxxinity that agreement, Vaxxinity to otherwise exploit peptide-based vaccines in the field human immunodeficiency virus (HIV), herpes licensed under the Platform License certain designer the Company issued to UBI a warrant to purchase Class A common stock (the “UBI Warrant”). The Company considered ASC 805, “Business Combinations” (“ASC 805”) and ASC 730, “Research and Development” (“ASC 730”) in determining how to a related party in exchange for a license agreement. The majority of the voting interests in the related party and that of the Company were held by control transaction, party did not have any basis in the assets licensed, there was no accounting impact for the Company. In connection with error relating to the recording of the UBI Warrant The UBI intellectual property’ 13.3 0.1 However, as noted above, the UBI Warrant Platform License Agreement was zero. As a result, the The Company has concluded that the error is not material to any previously issued financial statements. Indemnification Agreements In the ordinary vendors, lessors, breach of such into indemnification agreements other things, to indemnify them against certain liabilities that may arise by reason of their status or maximum potential amount of future payments many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have flows, and it has not accrued any liabilities related to such obligations as of December 31, 2021. Legal Proceedings From December 31, 2021, the Company was not a party to any material legal matters or claims.

Benefit Plans

Benefit Plans	12 Months Ended
	Dec. 31, 2021
Benefit Plans [Abstract]
Benefit Plans	17. Benefit Plans In substantially all annual compensation on a pre-tax basis. The Company does not make matching contributions to the Plan. The Company offers its Ireland-based employees a portion of their 5 % of each of the years ended December 31, 2021 and 2020, the Company contributed less than $ 0.1

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	18. Related Party Transactions The Company has to including the the benefits assessment of whether unrelated third parties. the transaction is not inconsistent with the interests of the Company and its shareholders. The Company has related Asia (“UBI-Asia”), UBI Pharma, Inc. (“UBI-P”), United BioPharma, Inc (“UBP”) and UBI IP Holding (“UBI-IP”). As of 43 % of both UBI and the Company were held by a group of immediate family members, and as such the entities are under common control. These related parties are governed by various Master Services Agreements (“MSA”) detailed below. UBI MSA - UBI provides research, UBI for the production and shipment of the Company’s diagnostic test kits. UBIA MSA - UBI-Asia for manufacturing, quality control, testing, validation, and supply services. UBP MSA - United BioPharma, Inc provide the Company with manufacturing, testing and validation. COVID MSA (“COVID MSA”) Company’s COVID-19 program and provides research, development, manufacturing and back office administrative services to the Company. COVID-19 technologies related to diagnostics, vaccines, and therapies for COVID-19. The MSA established the terms under which UBI-Asia provides research, development, testing and manufacturing services to manufacturing services to the Company. Total amounts due to 19.4 8.0 due from related 0.4 0.4 fees incurred were $ 35.4 18.2 Taiwan Centers for Disease Control Grant (“Taiwan UBI-Asia, which is responsible by the Taiwan COVID-19 vaccine clinical trial be reimbursed based on the achievement of certain milestones as provided in the agreement. The Company provides administrative services to UBI-IP. technical services mostly for legal services on behalf UBI-IP. no markup. Total follows (in thousands): December 31, 2021 2020 Consolidated balance sheet Assets Prepaid expenses and other current assets $ 3,517 $ 2,867 Property and equipment, net 337 725 Accrued expenses — 285 Amounts due from related parties 393 361 Liabilities Amounts due to related parties 19,407 8,004 Years 2021 2020 Consolidated statement of operations Revenue $ — $ 162 Cost of revenue — 52 Operating expenses Research and development Services provided by related parties 41,430 17,987 Taiwan CDC grant reimbursement from related party (7,199) (2,948) General and administrative Services provided by related parties 1,173 3,147

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	19. Subsequent Events The Company has evaluated subsequent events that require disclosure in the accompanying consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2021
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation
Foreign currency translation	Foreign currency translation The functional currency rates and monetary assets and liabilities are accounts are (losses) gains in the consolidated statements of operations.
Segment information	Segment information Operating segments are reviewed by assessing performance. The Company’s as a single operating segment and has one reportable segment.
Use of estimates	Use of estimates The preparation of consolidated and assumptions that affect the reported amounts of assets and liabilities and the consolidated financial statements and the reported amounts of expenses during within these consolidated financial statements include, but are not limited to, the estimated fair value of the Company’s common and convertible notes payable, simple agreements for future equity, warrant liabilities, stock-based compensation, income tax valuation allowance and the trends and other market-specific management evaluates estimates or assumptions.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be equivalents with financial institutions, in of the Company’s cash management policy cash flow requirements, and to attain a market rate of return.
Restricted cash	Restricted cash December 31, 2021 2020 Cash and cash equivalents $ 144,885 $ 31,143 Restricted cash 172 55 Total cash, cash equivalents and restricted cash $ 145,057 $ 31,198
Concentration of credit risk	Concentration of credit risk Financial instruments Cash equivalents are and accredited financial associated with form of a money market account with a financial institution that management believes to be creditworthy. The Company is dependent on contract manufacturers, several of whom are considered to be related parties, for manufacturing, quality control, immunosorbent assay (“ELISA”) tests, and for research as research and manufacturers.
Accounts receivable	Accounts receivable
Property and equipment	Property and equipment Property and equipment are estimated useful life of the assets. The estimated useful life of property and equipment is as follows: Estimated Useful Life Airplane 15 years Facilities 15 years Furniture and fixtures 5 years Vehicles 5 years Laboratory and computer equipment 3 years Software 3 years Upon retirement or sale, the cost of assets resulting gain or incurred.
Impairment of long-lived assets	Impairment of long-lived assets Long-lived circumstances indicate deciding significant negative industry or review expected to recognized when estimated undiscounted future cash flows expected to result from the use of an asset The impairment loss would be discounted cash flows. To date, the Company has not recorded any impairment losses or disposals on long-lived assets.
Deferred offering costs	Deferred offering costs
Fair value measurements	Fair value measurements Certain assets and liabilities an asset or paid to transfer a liability (an transaction between market participants on the measurement date. Valuation use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets that are identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices corroborated by observable market data. Level 3—Unobservable inputs that are supported by assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.
Convertible notes payable	Convertible notes payable The Company issued payable at fair value in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”). The notes payable with related parties are from the over the term of the convertible notes using the effective interest method in the accompanying consolidated statements of operations.
Debt issuance costs	Debt issuance costs The Company records term of the debt using operations.
Simple Agreement for Future Equity - SAFE	Simple Agreement for Future Equity—SAFE The Company accounts for SAFEs at reporting period, with changes in fair value recognized in the accompanying consolidated statements of operations. On March 2, 2021,
Classification of convertible preferred stock	Classification of convertible preferred stock The Company by its terms. The Company’s convertible preferred stock is classified have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the control of the Company.
Revenue recognition	Revenue recognition The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts With Customers (“ASC 606”). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or consideration that with customers only when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Company assesses the evaluating management to make judgments about the individual promised goods or services, the intended benefit of good or distinct, an entity is required to combine that good or service with other promised goods or services or services that is distinct. If the consideration promised in a contract includes a variable amount, the Company will be variable consideration by using the most likely amount method and applies the constraint on variable consideration, which requires the amount included in the revenue recognized consideration included in the transaction price price. The Company recognizes as revenue the (or as) each performance obligation is satisfied, either at a of an output or input method. In the Company’s sole revenue contract, the performance obligation was satisfied at the point in time the data and related samples were made available for the customer’s review. For its sales of ELISA tests, the Company recognizes revenue once control is transferred upon delivery to the customer.
Taiwan Centers for Disease Control Grant	Taiwan Centers for Disease Control grant United managing COVID-19 vaccine development. trial in Taiwan. achievement activities involved in completing the clinical trials in relation to the milestones. The Company accounts for the amounts that have been received from the CDC as contra research and development expenses in the accompanying consolidated statements of operations.
Research and development	Research and development Research compensation and other corporate costs attributable to research and development activities and are expensed as incurred. The Company has entered into various research, development and manufacturing contracts, some of which are with related parties (see Note 18). These expenses as incurred. liabilities, the Company contracted costs. The Company’s historical accrual estimates have not been materially different from the actual costs.
Patent costs	Patent costs Patent-related costs relating to the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.
Stock-based compensation	Stock-based compensation The Company measures all stock-based awards granted to employees, directors and non-employees based on the fair of grant and recognizes compensation of the respective award. Forfeitures are accounted for as they occur. The Company classifies the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. Prior to value of its common stock was determined by its most recently available third-party valuations of common stock. There are significant judgments assumptions include sold shares of preferred the likelihood used in the valuations could result in different fair values of common stock at each valuation date.
Income taxes	Income taxes
Net loss per share	Net loss per share The Company of participating according to dividends declared or accumulated, and participation rights available to rights to receive dividends as if all income for the period had been distributed. Basic net period. Diluted net loss is computed by securities. Diluted net outstanding for restricted stock and convertible preferred stock are considered potential dilutive common stock and are excluded from the computation of net loss per share as their effect is anti-dilutive. The Company’s contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a diluted net loss per share is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to be outstanding if their effect is anti-dilutive.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Significant Accounting Policies [Abstract]
Restricted cash	December 31, 2021 2020 Cash and cash equivalents $ 144,885 $ 31,143 Restricted cash 172 55 Total cash, cash equivalents and restricted cash $ 145,057 $ 31,198
Useful life of property and equipment	Estimated Useful Life Airplane 15 years Facilities 15 years Furniture and fixtures 5 years Vehicles 5 years Laboratory and computer equipment 3 years Software 3 years

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Measurements [Abstract]
Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis	December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Money market account $ — $ — $ — $ — Total assets $ — $ — $ — $ — Liabilities: Convertible notes payable $ — $ — $ 10,356 $ 10,356 Convertible notes with related parties — — 14,324 14,324 SAFEs — — 24,335 24,335 Warrant liability — — 400 400 Total liabilities $ — $ — $ 49,415 $ 49,415 December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market account $ 139,794 $ — $ — $ 139,794 Total assets $ 139,794 $ — $ — $ 139,794
Schedule of Carrying Amounts and Estimated Fair Values of Financial Instruments	Convertible Notes Balance at December 31, 2019 $ 12,121 Issuance of convertible notes 12,040 Repayments (5,500) Change in fair value 5,761 Issuance costs (300) Amortization of issuance costs 83 Accrued interest 475 Balance at December 31, 2020 24,680 Issuance of convertible notes 2,000 Repayments (2,000) Change in fair value 2,667 Amortization of issuance costs 217 Accrued interest 168 Interest paid (187) Conversion to Series A preferred stock (27,545)
Schedule of Fair Value Measured on a Nonrecurring Basis	Convertible Notes Balance at December 31, 2019 $ 12,121 Issuance of convertible notes 12,040 Repayments (5,500) Change in fair value 5,761 Issuance costs (300) Amortization of issuance costs 83 Accrued interest 475 Balance at December 31, 2020 24,680 Issuance of convertible notes 2,000 Repayments (2,000) Change in fair value 2,667 Amortization of issuance costs 217 Accrued interest 168 Interest paid (187) Conversion to Series A preferred stock (27,545)
Schedule of Activity in Level 3	SAFE Liability Balance at December 31, 2019 $ — Issuance of SAFEs 39,355 Change in fair value 615 Conversion to Series Seed-2 convertible preferred stock (360) Conversion to Series A-2 convertible preferred stock (15,275) Balance at December 31, 2020 24,335 Change in fair value 8,365 Issuance of SAFEs 2,900 Conversion to Series A preferred stock (35,600) Warrant Liability Balance at December 31, 2019 $ — Issuance of Series A-1 preferred warrants 573 Exercise of warrants (214) Change in fair value 41 Balance at December 31, 2020 400 Change in fair value 214 Conversion to warrants for shares of Series A preferred stock (614)

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	December 31, 2021 2020 Deposits $ 4,379 $ 10 Prepaid materials and supplies 4,131 3,302 Other 341 832 $ 8,851 $ 4,144

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property and Equipment [Abstract]
Property and Equipment, Net	December 31, 2021 2020 Airplane $ 11,983 $ 11,983 Laboratory and computer equipment 1,831 969 Software 168 — Vehicles 87 — Facilities, furniture and fixtures 85 84 Total property and equipment 14,154 13,036 Less: accumulated depreciation (1,981) (878) Property and equipment, net $ 12,173 $ 12,158

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued expenses and other current liabilities	December 31, 2021 2020 Accrued bonuses $ 2,294 $ 2,187 Accrued external research and development 1,501 296 Accrued professional fees and other 692 228 Accrued interest 32 33 $ 4,519 $ 2,744

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Other Liabilities	December 31, 2021 2020 Accrued tax provision 236 236 Accrued rent 1 13 $ 237 $ 249

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Payable [Abstract]
Convertible Notes	Convertible Notes Principal Amount Payable Change in Fair Value Accrued Interest Issuance Conversion to Standard Related Party Standard Related Party Standard Related Party Costs Series A Balance December 31, 2019 $ 11,170 $ 510 $ 33 $ 26 $ 378 $ 4 $ — $ — $ 12,121 Additions 2,040 10,000 1,884 3,822 560 179 (300) — 18,185 Settlements (5,500) — 55 — (264) — — — (5,709) Amortization — — — — — — 83 — 83 December 31, 2020 7,710 10,510 1,972 3,848 674 183 (217) — 24,680 Additions — 2,000 812 1,855 58 110 — — 4,835 Settlements (2,000) — — — (187) — — — (2,187) Amortization — — — — — — 217 — 217 Conversion of Convertible Notes to Series A preferred stock (5,710) (12,510) (2,784) (5,703) (545) (293) — (27,545) (27,545) December 31, 2021 $ — $ — $ — $ — $ — $ — $ — $ (27,545) $ —

Notes payable (Tables)

Notes payable (Tables)	12 Months Ended
	Dec. 31, 2021
Notes payable with related parties [Abstract]
Activity of the notes payable with related parties	2018 Related Notes and 2019 Executive Note Related Party Principal Accrued Interest Balance December 31, 2019 $ 2,100 $ 88 $ 2,188 Additions — 106 106 December 31, 2020 2,100 194 2,294 Accrued interest — 19 19 Repayment (100) — (100) Interest paid — (8) (8) Conversion (2,000) (205) (2,205) December 31, 2021 $ — $ — $ —
Schedule of Maturities of Notes Payable	Amount 2022 $ 429 2023 444 2024 458 2025 9,552 $ 10,883

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2021
Common Stock [Abstract]
Reserved Shares of Common Stock for Issuance	December 31, 2021 2020 Series Seed preferred — 7,831,528 Series Seed-1 preferred — 22,876,457 Series Seed-2 preferred — 14,615,399 Series A-1 preferred — 1,871,511 Series A-2 preferred — 6,307,690 Options issued and outstanding 21,387,909 9,276,399 Options available for future grants 7,209,538 1,897,049 Warrants issued and outstanding 1,928,020 86,186 30,525,467 64,762,219

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Equity Incentive Plan [Abstract]
Weighted Average Assumptions	December 31, 2021 2020 Risk-free interest rate 0.59% - 1.35% 0.34% - 0.38% Expected term (in years) 5.00 - 6.30 5.60 - 6.08 Expected volatility 71.60% - 93.40% 70.90% - 86.84% Expected dividend yield 0.00% 0.00%
Summary of Stock Option Activity	Number of Stock Options Outstanding Weighted Price Per Share Weighted Contractual Term (years) Aggregate Intrinsic Value (in thousands) Balance at December 31, 2019 7,610,289 $ 0.33 8.6 $ 2,357 Granted 2,672,152 1.17 Exercised (283,290) 0.29 Forfeited (722,752) 0.29 Balance at December 31, 2020 9,276,399 $ 0.60 7.6 $ 8,415 Granted 13,482,915 8.20 Exercised (186,204) 0.91 Forfeited (1,185,201) 2.98 Balance at December 31, 2021 21,387,909 $ 5.25 7.4 $ 49,684 Options vested and exercisable at December 31, 2021 13,439,566 $ 4.40 6.8 $ 37,969
Summary of Restricted Stock Activity	Number of Shares Weighted Average Grant Date Fair Value Per Share Unvested at December 31, 2020 15,405 $ 0.50 Vested (15,405) (0.50) Unvested at December 31, 2021 — $ —
Schedule of Stock-Based Compensation Expense for Stock Options	Years 2021 2020 Research and development $ 1,343 $ 243 General and administrative 29,069 771 Total stock-based compensation expense $ 30,412 $ 1,014

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Taxes [Abstract]
Schedule of Loss Before Income Taxes	Years Losses before taxes 2021 2020 Domestic entities $ (128,538) $ (31,053) Entities outside the U.S. (8,636) (8,904) (137,175) $ (39,957)
Schedule of Income Tax Expense	Years 2021 2020 Current: Federal $ — $ — State and local — — Foreign — — Total current tax expense — — Deferred tax (benefit): Federal — — State and local — — Foreign — — Total deferred tax (benefit) — —
Reconciliation of Income Tax Percent	Years 2021 2020 Income taxes at statutory rate 21.00 % 21.00 % State income taxes, net of federal benefit 0.50 % 0.29 % Stock compensation (3.65) % % Foreign rate differential (0.74) % (4.06) % Uncertain tax positions 0.00 % 0.00 % Other (1.90) % (0.36) % Change in valuation allowance (15.21) % (16.87) % Provision for income taxes 0.00 % 0.00 %
Schedule of Deferred Tax Assets	As of December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 32,405 $ 12,373 Compensation accruals 1,735 377 Other 27 627 Total deferred tax assets 34,167 13,377 Less: valuation allowance (34,106) (13,247) Net deferred tax assets $ 61 $ 130 Deferred tax liabilities: Depreciation $ (61) $ (130) Net deferred tax liabilities (61) (130) Net deferred income taxes $ — $ —
Schedule of Unrecognized Tax Benefits	Years 2021 2020 Uncertain tax position liability at the beginning of the year $ 652 $ 646 Increases (decreases) related to tax positions taken during current period — 6 Uncertain tax position liability at the end of the year $ 652 $ 652

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Net Loss Per Share [Abstract]
Schedule of Excluded Potential Common Shares from Computation of Diluted Net Loss Per Share	December 31, 2021 2020 Series Seed preferred — 7,831,528 Series Seed-1 preferred — 22,876,457 Series Seed-2 preferred — 14,615,399 Series A-1 preferred — 1,871,511 Series A-2 preferred — 6,307,690 Unvested restricted stock — 23,970 Options and RSUs issued and outstanding 21,387,909 14,434,095 Warrants issued and outstanding stock 1,928,020 134,106 23,315,929 68,094,756

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Schedule of Related Party Operating Activity	December 31, 2021 2020 Consolidated balance sheet Assets Prepaid expenses and other current assets $ 3,517 $ 2,867 Property and equipment, net 337 725 Accrued expenses — 285 Amounts due from related parties 393 361 Liabilities Amounts due to related parties 19,407 8,004 Years 2021 2020 Consolidated statement of operations Revenue $ — $ 162 Cost of revenue — 52 Operating expenses Research and development Services provided by related parties 41,430 17,987 Taiwan CDC grant reimbursement from related party (7,199) (2,948) General and administrative Services provided by related parties 1,173 3,147

Nature of the Business (Narrati

Nature of the Business (Narrative) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)
Nature of Business Disclosures [Line Items]
Proceeds from issuance of convertible notes payable with related parties | $	$ 2,000	$ 12,040
Repayment of convertible notes | $	$ 2,000	5,500
Issuance of stock, shares	32,505,306
Cash and cash equivalents | $	$ 144,885	31,143
Net Income Loss | $	(137,175)	(39,957)
Accumulated deficit | $	$ (229,481)	$ (92,306)
Reverse stock split	1.556
Class A Common Stock [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares	6,000,000
Share Price | $ / shares	$ 13
Underwriters [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares	900,000
Underwriters [Member] | Class A Common Stock [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares	537,711
Share Price | $ / shares	$ 71.1
UNS. [Member]
Nature of Business Disclosures [Line Items]
Note conversion ratio	3.4233
COVAXX [Member]
Nature of Business Disclosures [Line Items]
Note conversion ratio	0.2191
ConvertiblePreferredStockSharesIssuedUponConversion	3.4233
Debt Conversion Converted Instrument Shares Issued 1	4,047,344

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Summary of Significant Accounting Policies [Abstract]
Restricted cash	$ 172	$ 55
Lessee, Lease, Description [Line Items]
Operating Lease Liability	$ 200

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Restricted Cash) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Summary of Significant Accounting Policies [Abstract]
Cash and cash equivalents	$ 144,885	$ 31,143
Restricted cash	172	55
Total cash, cash equivalents and restricted cash	$ 145,057	$ 31,198	$ 476

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Useful Life of Property and Equipment) (Details)	12 Months Ended
	Dec. 31, 2021
Air Transportation Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	15 years
Laboratory And Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Furniture And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021
Class Of Warrant Or Right [Line Items]
Fair value asset transfers, level 1 to level 2		$ 0
Fair value asset transfers, level 2 to level 1		0
Fair value liability transfers, level 1 to level 2		0
Fair value liability transfers, level 2 to level 1		0
Fair value of preferred stock issued on conversion date	$ 15,600,000	$ 35,600,000
Series A-1 Preferred [Member]
Class Of Warrant Or Right [Line Items]
Number of shares available to purchase from vested warrants	71,862	205,970
Warrants, exercise price	$ 0.003	$ 0.003
Cash proceeds from warrants exercised	$ 1,000,000
Warrant outstanding	134,106

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable	$ 139,794	$ 10,356
Simple agreement for future equity	0	24,335
Warrant liability	0	400
Liabilities	139,794	49,415
Cash and cash equivalents	144,885	31,143
Convertible Notes Payable, Related Party, Fair Value		14,324
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable	139,794
Liabilities	139,794
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities	0
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable		10,356
Simple agreement for future equity		24,335
Warrant liability		400
Liabilities	$ 0	49,415
Convertible Notes Payable, Related Party, Fair Value		$ 14,324

Fair Value Measurements (Sche_2

Fair Value Measurements (Schedule of Activity in Level 3, Convertible Notes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Repayment of convertible notes	$ 2,000	$ 5,500
Payments Of Debt Issuance Costs	300	0
Convertible Debt [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance	24,680	12,121
Proceeds from issuance of convertible notes payable	2,000	12,040
Repayment of convertible notes	2,000	5,500
Debt, Change In Fair Value	2,667	5,761
Payments Of Debt Issuance Costs	217	300
Amortization Of Financing Costs And Discounts	168	83
Interest On Convertible Debt Net Of Tax	187	475
Debt, Convesion Of Debt Fair Value	$ (27,545)
Balance		$ 24,680

Fair Value Measurements (Sche_3

Fair Value Measurements (Schedule of Activity in Level 3, SAFE Arrangements) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in fair value	$ (8,365)	$ (615)
Level 3 [Member] | SAFE Arrangements [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	24,335	0
Issuance of SAFEs	2,900	39,355
Change in fair value	8,365	615
Balance	0	24,335
Level 3 [Member] | SAFE Arrangements [Member] | Series Seed-2 Stock [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Conversion to Series A-1 convertible preferred stock		360
Level 3 [Member] | SAFE Arrangements [Member] | Series A-2 Stock [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Conversion to Series A-1 convertible preferred stock		$ 15,275
Level 3 [Member] | SAFE Arrangements [Member] | Series A Preferred Stock [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Conversion to Series A-1 convertible preferred stock	$ 35,600

Fair Value Measurements (Sche_4

Fair Value Measurements (Schedule of Activity in Level 3, Warrants) (Details) - Level 3 [Member] - Warrants [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 400	$ 0
Issuance of Series A-1 preferred warrants		573
Change in fair value	214	41
Conversion Of Warrants	(614)	(214)
Balance	$ 0	$ 400

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expenses and Other Current Assets [Line Items]
Supplies	$ 10	$ 4,379
Related Party [Member]
Prepaid Expenses and Other Current Assets [Line Items]
Supplies	1,000
Vaccine Development [Member]
Prepaid Expenses and Other Current Assets [Line Items]
Supplies	$ 2,500

Prepaid Expenses and Other Cu_4

Prepaid Expenses and Other Current Assets (Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid materials and supplies	$ 10	$ 4,379
Deposits	3,302	4,131
Other	832	341
Total	$ 4,144	$ 8,851

Property and Equipment (Narrati

Property and Equipment (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Depreciation	$ 1,102	$ 717

Property and Equipment (Propert

Property and Equipment (Property and Equipment, Net) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment	$ 14,154	$ 13,036
Less accumulated depreciation	(1,981)	(878)
Property and equipment, net	12,173	12,158
Air Transportation Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	11,983	11,983
Laboratory And Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	1,831	969
Software And Software Development Costs [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	168,000	0
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	87,000	0
Furniture And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 85,000	$ 84,000

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Accrued Expenses and Other Current Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued payroll and benefits	$ 2,294	$ 2,187
Accrued External Research And Development	1,501	296
Accrued professional fees and other	692	228
Accrued interest	32	33
Total	$ 4,519	$ 2,744

Other Long-Term Liabilities (Na

Other Long-Term Liabilities (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Other Liabilities Disclosure [Abstract]
Accrued Payroll Taxes Current And Noncurrent	$ 0.2	$ 0.2
Income Tax Examination Penalties And Interest Accrued	$ 0.2

Other Long-Term Liabilities (Ot

Other Long-Term Liabilities (Other Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Other Liabilities Disclosure [Abstract]
Accrued tax provision	$ 236	$ 236
Lease liability	13	1
Total	$ 249	$ 237

Convertible Notes Payable (Narr

Convertible Notes Payable (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Proceeds from issuance of convertible notes payable with related parties	$ 2,000	$ 12,040
Convertible Debt [Member]
Debt Instrument [Line Items]
Interest Expense, Debt	200	700
Change in fair value	$ 2,700	$ 5,700
Convertible Debt [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument Interest Rate Stated Percentage	4.80%
Convertible Debt [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument Interest Rate Stated Percentage	6.00%

Convertible Notes Payable (Conv

Convertible Notes Payable (Convertible Notes) (Details) - Convertible Debt [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 24,680	$ 12,121
Additions	4,835	18,185
Settlements	(2,187)	(5,709)
Amortization	217	83
Conversion of Convertible Notes to Series A preferred stock	(27,545)
Balance	0	24,680
Issuance Costs [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	(217)	0
Additions	0	(300)
Settlements	0	0
Amortization	217	83
Conversion of Convertible Notes to Series A preferred stock	0
Balance	0	(217)
Conversion to Series A Preferred [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	0	0
Additions	0	0
Settlements	0	0
Amortization	0	0
Conversion of Convertible Notes to Series A preferred stock	(27,545)
Balance	(27,545)	0
Principal Amount [Member] | Standard [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	7,710	11,170
Additions	0	2,040
Settlements	(2,000)	(5,500)
Amortization	0	0
Conversion of Convertible Notes to Series A preferred stock	(5,710)
Balance	0	7,710
Principal Amount [Member] | Related Party [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	10,510	510
Additions	2,000	10,000
Settlements	0	0
Amortization	0	0
Conversion of Convertible Notes to Series A preferred stock	(12,510)
Balance	0	10,510
Change In Fair Value [Member] | Standard [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	1,972	33
Additions	812	1,884
Settlements	0	55
Amortization	0	0
Conversion of Convertible Notes to Series A preferred stock	(2,784)
Balance	0	1,972
Change In Fair Value [Member] | Related Party [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	3,848	26
Additions	1,855	3,822
Settlements	0	0
Amortization	0	0
Conversion of Convertible Notes to Series A preferred stock	(5,703)
Balance	0	3,848
Accrued Interest [Member] | Standard [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	674	378
Additions	58	560
Settlements	(187)	(264)
Amortization	0	0
Conversion of Convertible Notes to Series A preferred stock	(545)
Balance	0	674
Accrued Interest [Member] | Related Party [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	183	4
Additions	110	179
Settlements	0	0
Amortization	0	0
Conversion of Convertible Notes to Series A preferred stock	(293)
Balance	$ 0	$ 183

Notes payable (Notes payable wi

Notes payable (Notes payable with related parties) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Repayment	$ (414)	$ (202)
Additions	(31)	(1,743)
2019 Related Notes and 2020 Executive Note [Member]
Debt Instrument [Line Items]
Beginning balance	2,294	2,188
Debt Instrument Increase Accrued Interest	19
Repayment	(100)
Interest paid	(8)
Conversion	(2,205)
Additions		106
Ending balance	0	2,294
2019 Related Notes and 2020 Executive Note [Member] | Principal Amount [Member]
Debt Instrument [Line Items]
Beginning balance	2,100	2,100
Debt Instrument Increase Accrued Interest	0
Repayment	(100)
Interest paid	0
Conversion	(2,000)
Additions		0
Ending balance	0	2,100
2019 Related Notes and 2020 Executive Note [Member] | Accrued Interest [Member]
Debt Instrument [Line Items]
Beginning balance	194	88
Debt Instrument Increase Accrued Interest	19
Repayment	0
Interest paid	(8)
Conversion	(205)
Additions		106
Ending balance	$ 0	$ 194

Notes payable (Narrative) (Deta

Notes payable (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Proceeds from issuance of convertible notes payable with related parties	$ 2,000	$ 12,040
Payments Of Debt Issuance Costs	300	0
2018 Related Notes and Reorg. Convertible Notes [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties				$ 2,000
Debt Instrument Interest Rate Stated Percentage				5.00%
Interest Expense, Debt	100	100
2019 Executive Note [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties			$ 100
Debt Instrument Interest Rate Stated Percentage			5.00%
Notes Payable, Airplane [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties		$ 11,500
Debt Instrument Interest Rate Stated Percentage		3.40%
Interest Expense, Debt	400	$ 200
Debt Instrument Periodic Payment Interest		70
Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid	9,400
Payments Of Debt Issuance Costs		$ 300
Debt Instrument Increase Accrued Interest	100
Paycheck Protection Program [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties	$ 300

Notes payable (Carrying Value)

Notes payable (Carrying Value) (Details) - Note, 2025 [Member] - Notes Payable [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Principal	$ 10,883	$ 11,298
Unamortized debt issuance cost	184	237
Total	10,699	11,061
Less: current portion	(376)	(362)
Note payable, net of current portion and debt issuance cost	$ 10,323	$ 10,699

Notes payable (Annual Principal

Notes payable (Annual Principal Payments) (Details) - Note, 2025 [Member] - Notes Payable [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
2021	$ 429
2022	444
2023	458
2024	9,552
Total	$ 10,883	$ 11,298

Simple Agreement for Future E_2

Simple Agreement for Future Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Aug. 31, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Simple Agreement for Future Equity [Line Items]
Simple agreement for future equity			$ 0	$ 24,335
Shares issued			32,505,306
Loss on fair value of investment			$ (8,365)	(615)
SAFE 1 [Member]
Simple Agreement for Future Equity [Line Items]
Simple agreement for future equity		$ 400
SAFE 2 [Member]
Simple Agreement for Future Equity [Line Items]
Simple agreement for future equity	$ 14,700
Shares issued	6,307,690
Share Price	$ 2.3241
SAFE 3 [Member]
Simple Agreement for Future Equity [Line Items]
Simple agreement for future equity			2,900	$ 24,300
Minimum value of qualified financing, equity financing provision			$ 50,000
Series Seed-2 Stock [Member] | SAFE 1 [Member]
Simple Agreement for Future Equity [Line Items]
Shares issued		463,162
Share Price		$ 0.7773

Convertible Preferred Stock (Na

Convertible Preferred Stock (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Aug. 31, 2020
Class Of Stock [Line Items]
Preferred stock, shares authorized/designated	50,000,000	57,298,376
Preferred stock, par value	$ 0.0001	$ 0.0001
Safe 2 [Member]
Class Of Stock [Line Items]
Share Price			$ 2.3241
Series A Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred stock, shares issued	0	0
Preferred stock, shares authorized/designated	0	0
Amended Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred stock, shares issued	15,365,574
Proceeds from Issuance Initial Public Offering	$ 122.8
Share Price	$ 8
ConvertiblePreferredStockSharesIssuedUponConversion	3.4233
Preferred stock, shares authorized/designated	50,000,000
Preferred stock, par value	$ 0.0001
Amended Preferred Stock [Member] | COVAXX [Member]
Class Of Stock [Line Items]
ConvertiblePreferredStockSharesIssuedUponConversion	0.2191

Convertible Preferred Stock (Sc

Convertible Preferred Stock (Schedule of Preferred Stock) (Details) - shares	Dec. 31, 2021	Nov. 14, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Preferred stock, share outstanding		77,588,669
Common Stock Issuable Upon Conversion	49,864,120
Series A Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred stock, share outstanding		62,223,095	0
Common Stock Issuable Upon Conversion	39,989,083
Series B Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred stock, share outstanding	0		0
Series B Preferred Stock Issued March 2021 [Member]
Class Of Stock [Line Items]
Preferred stock, share outstanding		9,923,711
Common Stock Issuable Upon Conversion	6,377,699
Series B Preferred Stock Issued June 2021 [Member]
Class Of Stock [Line Items]
Preferred stock, share outstanding		5,441,863
Common Stock Issuable Upon Conversion	3,497,338

Common Stock (Narrative) (Detai

Common Stock (Narrative) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Issuance of stock, shares	32,505,306
Class A Common Stock [Member]
Class Of Stock [Line Items]
Issuance of stock, shares	6,000,000
Share Price	$ 13
Common stock, shares authorized	1,000,000,000	129,916,912
Common stock, par value	$ 0.0001	$ 0.0001
Class A Common Stock [Member] | Chief Executive Officer [Member]
Class Of Stock [Line Items]
Shares converted	2,874,983
Common Class B [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	100,000,000	10,999,149
Common stock, par value	$ 0.0001	$ 0.0001
Common Stock [Member] | Class A Common Stock [Member]
Class Of Stock [Line Items]
Issuance of stock, shares	6,537,711
Amended And Restated Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	1,100,000,000
Common stock, par value	$ 0.0001
Amended And Restated Common Stock [Member] | Class A Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	1,000,000,000
Amended And Restated Common Stock [Member] | Common Class B [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	100,000,000
UNS [Member] | Class A Common Stock [Member]
Class Of Stock [Line Items]
Issuance of stock, shares	60,360,523
Shares converted	0.2191
UNS [Member] | Common Class B [Member]
Class Of Stock [Line Items]
Issuance of stock, shares	10,999,149
Shares converted	3.4233

Common Stock (Reserved Share of

Common Stock (Reserved Share of Common Stock for Issuance) (Details) - shares	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Class Of Stock [Line Items]
Options issued and outstanding	21,387,909	9,276,399	7,610,289
Options [Member]
Class Of Stock [Line Items]
Options issued and outstanding		9,276,399
Options available for future grants		1,897,049
Warrants issued and outstanding to purchase shares of common stock		86,186
Reserved Shares of Common Stock		64,762,219
Series seed-1 convertible preferred shares [Member] | Options [Member]
Class Of Stock [Line Items]
Preferred stock		22,876,457
Series seed-2 convertible preferred shares [Member] | Options [Member]
Class Of Stock [Line Items]
Preferred stock		14,615,399
Series Seed Stock [Member]
Class Of Stock [Line Items]
Preferred stock	0	10,452
Series A Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred stock	0	0
Series A-1 Preferred [Member] | Options [Member]
Class Of Stock [Line Items]
Preferred stock		1,871,511
Series A-2 preferred [Member] | Options [Member]
Class Of Stock [Line Items]
Preferred stock		6,307,690
Series Seed Preferred [Member] | Options [Member]
Class Of Stock [Line Items]
Preferred stock		7,831,528
Options issued and outstanding	21,387,909
Options available for future grants	7,209,538
Warrants issued and outstanding to purchase shares of common stock	1,928,020
Reserved Shares of Common Stock	30,525,467

Equity Incentive Plan (Narrativ

Equity Incentive Plan (Narrative) (Details - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding	21,387,909	9,276,399	7,610,289
Options exercisable	13,439,566
Total stock-based compensation expense	$ 1,014,000	$ 30,412,000
Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant		1,897,049
Options outstanding		9,276,399
Minimum [Member] | Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	1 year
Employee and Non-Employees [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	4 years
2021 Stock Option and Grant Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized compensation cost	$ 26,800,000
Recognized over a weighted average period	3 years 3 months 18 days
2021 Stock Option and Grant Plan [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant	7,209,538
Intrincic value of options exercised	$ 100,000	$ 100,000
Weighted-average grant-date fair value per share of options granted	$ 4.21	$ 0.50
Total fair value of options vested	$ 24,500,000	$ 800,000
2021 Stock Option and Grant Plan [Member] | First Anniversary [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total fair value of options vested	5,439,700	6,799,625
2021 Stock Option and Grant Plan [Member] | First Anniversary [Member] | Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total fair value of options vested	$ 100,000	$ 100,000
2021 Stock Option and Grant Plan [Member] | Board of Directors [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options exercisable	815,955
Intrincic value of options exercised	$ 300,000
2021 Stock Option and Grant Plan [Member] | Class A Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Available for issuance under Plan	21,593,830
2021 Stock Option and Grant Plan [Member] | Class A Common Stock [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Available for issuance under Plan	8,700,000
Number of shares available for grant	7,209,538
Options outstanding	15,025,454
Options exercisable	8,652,630
2021 Stock Option and Grant Plan [Member] | Class A Common Stock [Member] | Employee and Non-Employees [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options exercisable	6,799,625
2021 Stock Option and Grant Plan [Member] | Common Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant	6,362,455
2021 Stock Option and Grant Plan [Member] | Common Class B [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding	6,362,455
Options exercisable	4,786,936
2021 Stock Option and Grant Plan [Member] | Common Class B [Member] | Employee and Non-Employees [Member] | Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding	5,983,670
Total fair value of options vested	$ 23,800,000

Equity Incentive Plan (Weighted

Equity Incentive Plan (Weighted Average Assumptions) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	0.59%	0.34%
Risk-free interest rate, maximum	1.35%	0.38%
Expected volatility, minimum	71.60%	70.90%
Expected volatility, maximum	93.40%	86.84%
Mei Mei Hu and Louis Reese [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	58.00%
Expected term (in years)	4 years 6 months
Expected volatility	75.00%
Cost Of Equity	25.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price	$ 10.07
Peter Diamandis [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	0.09%
Expected term (in years)	1 year
Expected volatility	90.00%
Cost Of Equity	25.00%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price	$ 4.12
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 3 months 18 days	6 years 29 days
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	5 years	5 years 7 months 6 days

Equity Incentive Plan (Summary

Equity Incentive Plan (Summary of Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Equity Incentive Plan [Abstract]
Number of stock options, outstanding	9,276,399	7,610,289
Number of stock options, Granted	13,482,915	2,672,152
Number of stock options, Exercised	(186,204)	(283,290)
Number of stock options, Forfeited	(1,185,201)	(722,752)
Number of stock options, outstanding	21,387,909	9,276,399	7,610,289
Number of stock options, Exercisable	13,439,566
Weighted price per share, outstanding	$ 0.60	$ 0.33
Weighted price per share, Granted	8.20	1.17
Weighted price per share, Exercised	0.91	0.29
Weighted price per share, Forfeited	2.98	0.29
Weighted price per share, outstanding	5.25	$ 0.60	$ 0.33
Weighted price per share,exercisable	$ 4.40
Weighted contractual term, outstanding	7 years 4 months 24 days	7 years 7 months 6 days	8 years 7 months 6 days
Weighted contractual term, exercisable	6 years 9 months 18 days
Aggregate intrinsic value, outstanding	$ 49,684	$ 8,415	$ 2,357
Aggregate intrinsic value, exercisable	$ 37,969

Equity Incentive Plan (Summar_2

Equity Incentive Plan (Summary of Restricted Stock Activity) (Details)	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Equity Incentive Plan [Abstract]
Unvested, Number of Shares, Begining Balance | shares	15,405
Vested, Number of Shares | shares	(15,405)
Unvested, Number of Shares, Ending Balance | shares	0
Unvested, Weighted average grant date fair value per share, beginning balance | $ / shares	$ 0.50
Vested, weighted average grant date fair value per share | $ / shares	(0.50)
Unvested, Weighted average grant date fair value per share, ending balance | $ / shares	$ 0

Equity Incentive Plan (Schedule

Equity Incentive Plan (Schedule of Stock-Based Compensation Expense for Stock Options) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 1,014	$ 30,412
Research And Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	243	1,343
General And Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 771	$ 29,069

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Income tax expense	$ 0	$ 0
Valuation allowance increase	20,900	$ 6,700
Unrecognized tax benefits that would impact effective tax rate	$ 100
Effective Income Tax Rate Continuing Operations	0.00%	0.00%
Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate	$ 600
Income Tax Examination Penalties And Interest Accrued	200
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	44,500	$ 134,600
Foreign [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 24,000	$ 20,200

Income Taxes (Schedule of Loss

Income Taxes (Schedule of Loss Before Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Abstract]
United States	$ (128,538)	$ (31,053)
Foreign	(8,636)	(8,904)
Total	$ (137,175)	$ (39,957)

Income Taxes (Reconciliation of

Income Taxes (Reconciliation of Income Tax Percent) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Abstract]
U.S. federal statutory income tax rate	21.00%	21.00%
State and local taxes, net of federal benefits	0.50%	0.29%
Foreign rate differential	(0.74%)	(4.06%)
Uncertain tax positions	0.00%	0.00%
Other	(1.90%)	(0.36%)
Change in valuation allowance	(15.21%)	(16.87%)
Effective income tax rate	0.00%	0.00%

Income Taxes (Schedule of Defer

Income Taxes (Schedule of Deferred Tax Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Abstract]
Net operating loss carryforwards	$ 32,405	$ 12,373
Compensation accruals	1,735	377
Other temporary differences	27	627
Gross deferred tax assets	34,167	13,377
Valuation allowance	(34,106)	(13,247)
Net deferred tax assets	61	130
Deferred Income Tax Liabilities	61	130
Deferred Tax Liabilities	$ 61	$ 130

Income Taxes (Schedule of Unrec

Income Taxes (Schedule of Unrecognied Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Abstract]
Beginning balance, January 1	$ 652	$ 646
Gross increase, tax positions in current period	0	6
Ending balance, December 31	$ 652	$ 652

Net Loss Per Share (Schedule of

Net Loss Per Share (Schedule of Excluded Potential Common Shares from Computation of Diluted Net Loss Per Share) (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	68,094,756	23,315,929
Series Seed Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	7,831,528	0
Series Seed-1 Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	22,876,457	0
Series Seed-2 Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	14,615,399	0
Series A-1 Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	1,871,511	0
Series A-2 Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	6,307,690	0
Unvested restricted stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	23,970	0
Options issued and outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	14,434,095	21,387,909
Warrants issued and outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	134,106	1,928,020

Commitments and Contingencies (

Commitments and Contingencies (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)ft²shares	Dec. 31, 2020USD ($)
Commitments And Contingencies [Line Items]
Security deposit	$ 0.1
Rent expense	$ 0.1	$ 0.1
Shares issued | shares	32,505,306
Lease in square feet | ft²	5,012
Lease obligation	$ 0.2
Project Grant	0.8
Grant, Accrued Liability, Current	0
Grant, Accrued Liability, NonCurrent	0
Grant, Decrease In Research And Development	0.1
Amortization Of Intangible Assets	0.1
Increase Decrease In Intangible Assets Current	13.3
Contract Research Organizations [Member]
Commitments And Contingencies [Line Items]
Remaining prepayments	1.6
Contract Manufacturing Organizations [Member]
Commitments And Contingencies [Line Items]
Remaining prepayments	$ 2.5

Benefit Plans (Narrative) (Deta

Benefit Plans (Narrative) (Details) - Foreign Plan [Member] - Personal Retirement Savings Account [Member] $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Defined Contribution Plan Disclosure [Line Items]
Company contribution percent	5.00%
Company contributions	$ 0.1

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Due to related parties	$ 19,400	$ 8,000
Service fees	35,400	18,200
Prepaid expenses	4,144	8,851
Due From Related Parties	$ 400	$ 400
UBI [Member]
Related Party Transaction [Line Items]
Percent of ownership	43.00%

Related Party Transactions (Sch

Related Party Transactions (Schedule of Related Party Operating Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Prepaid expenses and other current assets	$ 4,144	$ 8,851
Property and equipment, net	12,173	12,158
Revenue	66	557
Cost of revenue	1,937	52
Due From Related Parties	400	400
Due to related parties	19,400	8,000
UBI IP [Member] | Services Provided By Related Parties [Member]
Related Party Transaction [Line Items]
Prepaid expenses and other current assets	3,517	2,867
Property and equipment, net	337	725
Accrued expenses	0	285
Revenue	0	162
Cost of revenue	0	52
Reimbursement from related party	17,987	41,430
General and administrative	3,147	1,173
Due From Related Parties	393	361
Due to related parties	19,407	8,004
UBI IP [Member] | Taiwan CDC Grant [Member]
Related Party Transaction [Line Items]
Reimbursement from related party	$ (2,948)	$ (7,199)

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020$ / sharesshares
Subsequent Event [Line Items]
Options issued	13,482,915	2,672,152
Options issued, exercise price | $ / shares	$ 8.20	$ 1.17
Reverse stock split	1.556
Issuance of stock | $	$ 103
Shares issued	32,505,306
Common Class A [Member]
Subsequent Event [Line Items]
Shares issued	6,000,000

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Summary of Restatement-Statement of Operations) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Revenue	$ 66	$ 557
Cost of revenue	1,937	52
Gross (loss) profit	(1,871)	505
Research and development	71,379	20,570
General and administrative	51,825	12,217
Total operating expenses	123,204	32,787
Loss from operations	(125,075)	(32,282)
Interest expense, net	840	1,182
Change in fair value of convertible notes	2,667	5,761
Loss on foreign currency translation, net	(23)	(77)
Other (income) expense	12,100	7,675
Net loss	$ (137,175)	$ (39,957)
Net loss per share, basic and diluted	$ (1.79)	$ (0.61)

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Summary of Restatement-Statement of Stockholders' Deficit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Issuance of common stock upon exercise of stock options	$ 170	$ 79
Net loss	(137,175)	(39,957)
Stockholders' deficit	$ 128,619	$ (87,375)	$ (48,512)

Summary of Significant Accoun_9

Summary of Significant Accounting Policies (Summary of Restatement-Statement of Cash Flows) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Error Corrections And Prior Period Adjustments Restatement [Line Items]
Net loss	$ (137,175)	$ (39,957)
Depreciation	1,102	717
Stock-based compensation expense	280	0
Non-cash interest expense	0	582
Change in fair value of convertible notes	2,667	5,761
Accounts receivable	26	(26)
Prepaid expenses and other current assets	(4,704)	(3,488)
Accounts payable	2,174	(267)
Amounts due to related parties	(31)	(1,743)
Accrued expenses and other current liabilities	1,775	285
Other liabilities	(12)	94
Net cash used in operating activities	(80,990)	(33,910)
Purchase of property and equipment	(1,318)	(1,477)
Net cash used in investing activities	(1,318)	(1,477)
Proceeds from issuance of convertible notes payable with related parties	2,000	12,040
Proceeds from Paycheck Protection Program	257	0
Proceeds from exercise of stock options	79	170
Net cash provided by financing activities	66,109	196,167
Increase in cash, cash equivalents, and restricted cash	30,722	113,859
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance	31,198	476
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance	$ 145,057	$ 31,198